NASDAQ:DRTS Alpha Tau Medical (DRTS) Stock Price, News & Analysis → Who are Nvidia’s Silent Partners? (From Weiss Ratings) (Ad) Free DRTS Stock Alerts $2.65 -0.06 (-2.21%) (As of 05:17 PM ET) Add Compare Share Share Today's Range$2.61▼$2.7450-Day Range$2.37▼$3.0452-Week Range$2.15▼$4.80Volume6,055 shsAverage Volume34,223 shsMarket Capitalization$184.63 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Alpha Tau Medical alerts: Email Address Alpha Tau Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside344.4% Upside$12.00 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.51) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.79 out of 5 starsMedical Sector399th out of 921 stocksSurgical & Medical Instruments Industry53rd out of 97 stocks 3.5 Analyst's Opinion Consensus RatingAlpha Tau Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlpha Tau Medical has only been the subject of 1 research reports in the past 90 days.Read more about Alpha Tau Medical's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.06% of the float of Alpha Tau Medical has been sold short.Short Interest Ratio / Days to CoverAlpha Tau Medical has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alpha Tau Medical has recently decreased by 33.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlpha Tau Medical does not currently pay a dividend.Dividend GrowthAlpha Tau Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DRTS. Previous Next 3.0 News and Social Media Coverage News SentimentAlpha Tau Medical has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Alpha Tau Medical this week, compared to 0 articles on an average week.Search Interest1 people have searched for DRTS on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Alpha Tau Medical to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alpha Tau Medical insiders have not sold or bought any company stock.Percentage Held by Insiders39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.65% of the stock of Alpha Tau Medical is held by institutions.Read more about Alpha Tau Medical's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alpha Tau Medical are expected to decrease in the coming year, from ($0.51) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpha Tau Medical is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpha Tau Medical is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpha Tau Medical has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Alpha Tau Medical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” About Alpha Tau Medical Stock (NASDAQ:DRTS)Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Read More DRTS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRTS Stock News HeadlinesMay 23 at 4:46 AM | americanbankingnews.comAlpha Tau Medical (NASDAQ:DRTS) Receives Buy Rating from HC WainwrightMay 21 at 1:29 PM | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Alpha Tau Medical Ltd (DRTS)May 21 at 8:45 AM | globenewswire.comAlpha Tau to Present at the Jefferies Global Healthcare ConferenceMay 21 at 8:29 AM | finanznachrichten.deAlpha Tau Medical Ltd.: Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 20 at 4:01 PM | globenewswire.comAlpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 18, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS)May 13, 2024 | globenewswire.comAlpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal CancerMay 6, 2024 | globenewswire.comAlpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in GlasgowMay 1, 2024 | globenewswire.comAlpha Tau to Participate in May Investor ConferencesMarch 25, 2024 | globenewswire.comAlpha Tau to Present at the Jefferies Radiopharma Innovation SummitMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipating Alpha Tau Medical’s Clinical Milestones and Growth Potential in 2024March 7, 2024 | globenewswire.comAlpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 26, 2024 | globenewswire.comAlpha Tau to Participate in Barclays 26th Annual Global Healthcare ConferenceJanuary 8, 2024 | benzinga.comAlpha Tau Medical Stock (NASDAQ:DRTS), Quotes and News SummaryDecember 20, 2023 | finance.yahoo.comAlpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNovember 28, 2023 | finance.yahoo.comAlpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic CancerNovember 20, 2023 | finance.yahoo.comAlpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck CancerNovember 17, 2023 | markets.businessinsider.comAnalyst Ratings for Alpha Tau MedicalNovember 16, 2023 | msn.comAlpha Tau Medical GAAP EPS of $0.31October 30, 2023 | finance.yahoo.comAlpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing FacilitySeptember 16, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Alpha Tau Medical's (NASDAQ:DRTS) Cash Burn SituationSeptember 14, 2023 | stockhouse.comAlpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical CenterAugust 24, 2023 | finance.yahoo.comAlpha Tau Medical to Participate in September Investor ConferencesAugust 17, 2023 | finance.yahoo.comAlpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRTAugust 2, 2023 | finance.yahoo.comAlpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023See More Headlines Receive DRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today5/23/2024Next Earnings (Estimated)8/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:DRTS CUSIPN/A CIK1871321 Webhealthcarecapitalcorp.com Phone972-3577-4115FaxN/AEmployees121Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$23.00 Low Stock Price Target$8.00 Potential Upside/Downside+344.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.47% Return on Assets-27.07% Debt Debt-to-Equity Ratio0.07 Current Ratio11.60 Quick Ratio12.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.13 per share Price / Book2.39Miscellaneous Outstanding Shares69,670,000Free Float42,151,000Market Cap$188.11 million OptionableOptionable Beta0.75 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Uzi Sofer (Age 54)CEO & Chairman Comp: $630kMr. Raphi Levy (Age 39)Chief Financial Officer Comp: $424kMr. Amnon Gat (Age 49)Chief Operations Officer Comp: $340kMr. Peter M. Melnyk (Age 62)Chief Commercial Officer Comp: $376kDr. Robert B. Den M.D. (Age 45)Chief Medical Officer & Member of Scientific Advisory Board Comp: $401kMr. Ronen Segal (Age 51)Chief Technology Officer Comp: $380kProf. Yona Keisari (Age 77)Chief Scientific Officer & Member of Scientific Advisory board Ms. Rebecca BeckerVice President of legalProf. Itzhak Kelson (Age 84)Chief Physics Officer & Member of Scientific Advisory Board Ms. Yael Zeiger (Age 41)Corporate Controller More ExecutivesKey CompetitorsOrchestra BioMedNASDAQ:OBIOProfound MedicalNASDAQ:PROFCVRxNASDAQ:CVRXAVITA MedicalNASDAQ:RCELClearPoint NeuroNASDAQ:CLPTView All CompetitorsInstitutional OwnershipLevin Capital Strategies L.P.Bought 8,641 shares on 5/16/2024Ownership: 0.486%USAdvisors Wealth Management LLCBought 10,238 shares on 5/2/2024Ownership: 0.015%Satovsky Asset Management LLCSold 9,836 shares on 4/23/2024Ownership: 0.070%View All Institutional Transactions DRTS Stock Analysis - Frequently Asked Questions Should I buy or sell Alpha Tau Medical stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpha Tau Medical in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DRTS shares. View DRTS analyst ratings or view top-rated stocks. What is Alpha Tau Medical's stock price target for 2024? 4 Wall Street research analysts have issued twelve-month price targets for Alpha Tau Medical's stock. Their DRTS share price targets range from $8.00 to $23.00. On average, they anticipate the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 344.4% from the stock's current price. View analysts price targets for DRTS or view top-rated stocks among Wall Street analysts. How have DRTS shares performed in 2024? Alpha Tau Medical's stock was trading at $3.01 at the start of the year. Since then, DRTS shares have decreased by 10.3% and is now trading at $2.70. View the best growth stocks for 2024 here. When is Alpha Tau Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 26th 2024. View our DRTS earnings forecast. How were Alpha Tau Medical's earnings last quarter? Alpha Tau Medical Ltd. (NASDAQ:DRTS) announced its quarterly earnings results on Monday, May, 20th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. Who are Alpha Tau Medical's major shareholders? Alpha Tau Medical's stock is owned by many different retail and institutional investors. Top institutional investors include Levin Capital Strategies L.P. (0.49%), Satovsky Asset Management LLC (0.07%) and USAdvisors Wealth Management LLC (0.01%). How do I buy shares of Alpha Tau Medical? Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DRTS) was last updated on 5/23/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTrade**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis could mean the end of the U.S dollar…Colonial MetalsThis military-backed stock “owns” AI marketPorter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpha Tau Medical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
